Galectin Therapeutics Inc. (NASDAQ:GALT) CFO Jack W. Callicutt acquired 2,354 shares of the stock in a transaction dated Friday, May 31st. The stock was acquired at an average price of $4.28 per share, for a total transaction of $10,075.12. Following the completion of the transaction, the chief financial officer now directly owns 3,614 shares of the company’s stock, valued at $15,467.92. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:GALT opened at $3.91 on Tuesday. The stock has a market capitalization of $183.74 million, a P/E ratio of -10.29 and a beta of 3.31. Galectin Therapeutics Inc. has a 12 month low of $3.17 and a 12 month high of $9.49.

Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Friday, May 10th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. As a group, analysts anticipate that Galectin Therapeutics Inc. will post -0.52 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of the stock. IHT Wealth Management LLC increased its stake in Galectin Therapeutics by 52.7% during the first quarter. IHT Wealth Management LLC now owns 16,080 shares of the company’s stock worth $82,000 after acquiring an additional 5,550 shares during the last quarter. MML Investors Services LLC increased its stake in Galectin Therapeutics by 55.8% during the fourth quarter. MML Investors Services LLC now owns 26,926 shares of the company’s stock worth $92,000 after acquiring an additional 9,642 shares during the last quarter. Jane Street Group LLC bought a new stake in Galectin Therapeutics during the first quarter worth approximately $113,000. Jefferies Group LLC bought a new stake in Galectin Therapeutics during the first quarter worth approximately $137,000. Finally, Stratos Wealth Partners LTD. increased its stake in Galectin Therapeutics by 45.5% during the fourth quarter. Stratos Wealth Partners LTD. now owns 40,950 shares of the company’s stock worth $140,000 after acquiring an additional 12,796 shares during the last quarter. Institutional investors own 16.36% of the company’s stock.

A number of equities research analysts recently commented on GALT shares. ValuEngine upgraded Galectin Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, March 31st. B. Riley started coverage on Galectin Therapeutics in a research report on Wednesday, February 13th. They issued a “buy” rating and a $11.00 target price on the stock. Finally, Zacks Investment Research downgraded Galectin Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 20th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $9.42.

WARNING: “Insider Buying: Galectin Therapeutics Inc. (GALT) CFO Buys 2,354 Shares of Stock” was published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/insider-buying-galectin-therapeutics-inc-galt-cfo-buys-2354-shares-of-stock/3030987.html.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

Recommended Story: What is a conference call?

Insider Buying and Selling by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.